In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) closed the day trading at $3.42 up 4.27% from the previous closing price of $3.28. In other words, the price has increased by $4.27 from its previous closing price. On the day, 1.56 million shares were traded. BDTX stock price reached its highest trading level at $3.45 during the session, while it also had its lowest trading level at $3.29.
Ratios:
For a better understanding of BDTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.73 and its Current Ratio is at 8.73. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’25 when BIOTECH GROWTH N V sold 5,784,292 shares for $2.07 per share. The transaction valued at 11,997,749 led to the insider holds 2,733,547 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDTX now has a Market Capitalization of 194718656 and an Enterprise Value of 72641656. As of this moment, Black’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 1.038 whereas that against EBITDA is 9.087.
Stock Price History:
The Beta on a monthly basis for BDTX is 3.04, which has changed by -0.2532751 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, BDTX has reached a high of $5.69, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is 17.26%, while the 200-Day Moving Average is calculated to be 48.96%.
Shares Statistics:
Over the past 3-months, BDTX traded about 1.01M shares per day on average, while over the past 10 days, BDTX traded about 1087010 shares per day. A total of 56.89M shares are outstanding, with a floating share count of 43.34M. Insiders hold about 23.88% of the company’s shares, while institutions hold 58.24% stake in the company. Shares short for BDTX as of 1756425600 were 7025751 with a Short Ratio of 6.96, compared to 1753920000 on 6481415. Therefore, it implies a Short% of Shares Outstanding of 7025751 and a Short% of Float of 17.719999.
Earnings Estimates
The dynamic stock of Black Diamond Therapeutics Inc (BDTX) is currently being evaluated by a team of 5.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.13 and low estimates of -$0.24.
Analysts are recommending an EPS of between $0.49 and $0.26 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is -$0.77, with 5.0 analysts recommending between -$0.49 and -$1.04.
